Barclays PLC Vir Biotechnology, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Barclays PLC holds 550,186 shares of VIR stock, worth $4.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

550,186

Previous 550,186 -0.0%

Holding current value

$4.06 Million

Previous $4.12 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$7.26 - $10.7 $52,903 - $77,970	7,287 Added 1.34%	550,186 $4.12 Million
Q2 2024 Aug 14, 2024	SELL	$7.63 - $12.66 $3.6 Million - $5.97 Million	-471,780 Reduced 46.5%	542,899 $4.83 Million
Q1 2024 May 15, 2024	BUY	$8.6 - $11.9 $4.9 Million - $6.78 Million	569,985 Added 128.17%	1,014,679 $10.3 Million
Q4 2023 Feb 15, 2024	BUY	$7.76 - $10.29 $252,456 - $334,764	32,533 Added 7.89%	444,694 $4.48 Million
Q3 2023 Nov 07, 2023	BUY	$9.14 - $24.62 $2.09 Million - $5.63 Million	228,634 Added 124.58%	412,161 $3.86 Million
Q2 2023 Aug 03, 2023	SELL	$23.2 - $27.29 $1.14 Million - $1.34 Million	-48,975 Reduced 21.06%	183,527 $4.5 Million
Q1 2023 May 04, 2023	BUY	$22.26 - $30.85 $807,526 - $1.12 Million	36,277 Added 18.49%	232,502 $5.41 Million
Q4 2022 Feb 13, 2023	SELL	$19.96 - $28.22 $863,529 - $1.22 Million	-43,263 Reduced 18.06%	196,225 $4.97 Million
Q3 2022 Nov 03, 2022	BUY	$18.26 - $31.1 $3.85 Million - $6.55 Million	210,711 Added 732.22%	239,488 $4.62 Million
Q2 2022 Aug 12, 2022	SELL	$19.08 - $26.7 $1.38 Million - $1.93 Million	-72,114 Reduced 71.48%	28,777 $734,000
Q1 2022 May 16, 2022	BUY	$21.19 - $40.01 $2.14 Million - $4.04 Million	100,891 New	100,891 $2.6 Million

Others Institutions Holding VIR

# of Institutions

218

Shares Held

87M

Call Options Held

127K

Put Options Held

1.19M

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $979M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account